Literature DB >> 21601651

DNA demethylases: a new epigenetic frontier in drug discovery.

Nessa Carey1, C Joana Marques, Wolf Reik.   

Abstract

DNA methylation is one of the most extensively studied, and one of the most stable, of all epigenetic modifications. Two drugs that target DNA methyltransferase enzymes are licensed for clinical use in oncology but relatively little attention has focused on the enzymatic pathways by which DNA methylation can be reversed. Recent breakthroughs have identified at least two classes of enzymes that can achieve functional reversal. This review discusses the significance of DNA demethylation in a range of human diseases, the candidate proteins that mediate the demethylation and the opportunities and challenges in targeting these candidates to develop new therapeutics.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21601651     DOI： 10.1016/j.drudis.2011.05.004

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  19 in total

Review 1.  A decade of exploring the cancer epigenome - biological and translational implications.

Authors:  Stephen B Baylin; Peter A Jones
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

2.  Enterocyte-specific regulation of the apical nutrient transporter SLC6A19 (B(0)AT1) by transcriptional and epigenetic networks.

Authors:  Emrah Tümer; Angelika Bröer; Sarojini Balkrishna; Torsten Jülich; Stefan Bröer
Journal:  J Biol Chem       Date:  2013-10-11       Impact factor: 5.157

Review 3.  Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11.

Authors:  David F Tough; Huw D Lewis; Inmaculada Rioja; Matthew J Lindon; Rab K Prinjha
Journal:  Br J Pharmacol       Date:  2014-11       Impact factor: 8.739

4.  Global hypermethylation in fetal cortex of Down syndrome due to DNMT3L overexpression.

Authors:  Jie Lu; Monika Mccarter; Gewei Lian; Giuseppe Esposito; Elena Capoccia; Laurent C Delli-Bovi; Jonathan Hecht; Volney Sheen
Journal:  Hum Mol Genet       Date:  2016-02-23       Impact factor: 6.150

5.  Targeted DNA demethylation in vivo using dCas9-peptide repeat and scFv-TET1 catalytic domain fusions.

Authors:  Sumiyo Morita; Hirofumi Noguchi; Takuro Horii; Kazuhiko Nakabayashi; Mika Kimura; Kohji Okamura; Atsuhiko Sakai; Hideyuki Nakashima; Kenichiro Hata; Kinichi Nakashima; Izuho Hatada
Journal:  Nat Biotechnol       Date:  2016-08-29       Impact factor: 54.908

Review 6.  The Mechanism and Function of Epigenetics in Uterine Leiomyoma Development.

Authors:  Qiwei Yang; Aymara Mas; Michael P Diamond; Ayman Al-Hendy
Journal:  Reprod Sci       Date:  2015-04-28       Impact factor: 3.060

7.  HDAC inhibition imparts beneficial transgenerational effects in Huntington's disease mice via altered DNA and histone methylation.

Authors:  Haiqun Jia; Charles D Morris; Roy M Williams; Jeanne F Loring; Elizabeth A Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-22       Impact factor: 11.205

Review 8.  Role of ART in imprinting disorders.

Authors:  Ali Eroglu; Lawrence C Layman
Journal:  Semin Reprod Med       Date:  2012-04-27       Impact factor: 1.303

9.  Potential epigenetic mechanism(s) associated with the persistence of psychoneurological symptoms in women receiving chemotherapy for breast cancer: a hypothesis.

Authors:  Debra Lyon; Lynne Elmore; Noran Aboalela; Jacqueline Merrill-Schools; Nancy McCain; Angela Starkweather; R K Elswick; Colleen Jackson-Cook
Journal:  Biol Res Nurs       Date:  2013-04-11       Impact factor: 2.522

Review 10.  DNA methylation in Huntington's disease: Implications for transgenerational effects.

Authors:  Elizabeth A Thomas
Journal:  Neurosci Lett       Date:  2015-11-11       Impact factor: 3.046
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.